Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Bought by GSA Capital Partners LLP

GSA Capital Partners LLP raised its holdings in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) by 158.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 37,884 shares of the company’s stock after buying an additional 23,237 shares during the period. GSA Capital Partners LLP’s holdings in Cytek Biosciences were worth $210,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Millennium Management LLC raised its position in shares of Cytek Biosciences by 3,452.2% during the second quarter. Millennium Management LLC now owns 946,490 shares of the company’s stock worth $5,281,000 after purchasing an additional 919,845 shares during the period. Renaissance Technologies LLC purchased a new position in shares of Cytek Biosciences in the second quarter worth approximately $1,305,000. Squarepoint Ops LLC lifted its position in shares of Cytek Biosciences by 1,013.8% in the 2nd quarter. Squarepoint Ops LLC now owns 187,361 shares of the company’s stock valued at $1,045,000 after acquiring an additional 170,539 shares in the last quarter. Algert Global LLC boosted its stake in Cytek Biosciences by 133.2% in the 2nd quarter. Algert Global LLC now owns 295,275 shares of the company’s stock worth $1,648,000 after purchasing an additional 168,665 shares during the period. Finally, Deerfield Management Company L.P. Series C purchased a new position in Cytek Biosciences during the 2nd quarter worth approximately $869,000. Institutional investors and hedge funds own 69.46% of the company’s stock.

Cytek Biosciences Trading Up 1.4 %

Cytek Biosciences stock opened at $6.55 on Monday. Cytek Biosciences, Inc. has a 1-year low of $4.66 and a 1-year high of $9.87. The firm’s fifty day simple moving average is $5.52 and its 200-day simple moving average is $5.70. The company has a market capitalization of $843.71 million, a P/E ratio of -81.88 and a beta of 1.32.

Cytek Biosciences (NASDAQ:CTKB) last posted its earnings results on Tuesday, November 5th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.03. The company had revenue of $51.50 million for the quarter, compared to analyst estimates of $50.63 million. Cytek Biosciences had a negative return on equity of 2.58% and a negative net margin of 5.05%. During the same period last year, the company earned ($0.03) earnings per share. On average, equities research analysts predict that Cytek Biosciences, Inc. will post -0.06 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Piper Sandler increased their price objective on Cytek Biosciences from $8.00 to $8.50 and gave the stock an “overweight” rating in a research note on Monday, November 11th.

About Cytek Biosciences

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.